Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Peptide antigens derived from tumors have been observed to elicit protective immune responses, categorized as either tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Subunit cancer vaccines incorporating these antigens have shown promise in inducing protective immune responses, leading to cancer prevention or eradication. Over recent years, peptide-based cancer vaccines have gained popularity as a treatment modality and are often combined with other forms of cancer therapy. Several clinical trials have explored the safety and efficacy of peptide-based cancer vaccines, with promising outcomes. Advancements in techniques such as whole-exome sequencing, next-generation sequencing, and in silico methods have facilitated the identification of antigens, making it increasingly feasible. Furthermore, the development of novel delivery methods and a deeper understanding of tumor immune evasion mechanisms have heightened the interest in these vaccines among researchers. This article provides an overview of novel insights regarding advancements in the field of peptide-based vaccines as a promising therapeutic avenue for cancer treatment. It summarizes existing computational methods for tumor neoantigen prediction, ongoing clinical trials involving peptide-based cancer vaccines, and recent studies on human vaccination experiments.
Funding Information
  • Bulgarian national plan for recovery and resilience through the Bulgarian National Science Fund (BG-RRP-2.004-0004-C01, BG05M2OP001-1.001-0003)
  • the Science and Education for Smart Growth Operational Program (BG-RRP-2.004-0004-C01, BG05M2OP001-1.001-0003)

This publication has 102 references indexed in Scilit: